Sign in
CompletedNo phase

Integrating the Use of Calibration-Free Continuous Monitoring for Pregnancy Glucose Profiling: I-Profile Study

Key facts

Who runs it
KK Women's and Children's Hospital
Where
Singapore1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
240 people enrolled
Started
16 Oct 2018
Ended
31 Aug 2024
Type of study
Interventional, 2 groups
Treatments tested
  • Blinded Group
  • Unblinded group
Record updated
10 October 2024

Who can take part

Age
21 years to 65 years
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Participants who are Singapore citizens or Singapore Permanent Residents, and plan to be followed up throughout pregnancy and intend to deliver at KKH
  • Aged 21 and above
  • Singleton pregnancy

Who cannot take part

  • Have serious skin conditions (e.g. eczema) that precludes wearing the sensor for 14 days
  • Patients who have any other chronic disease such as chronic kidney disease
  • Unable to read or speak English

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aims to test the following hypotheses in a longitudinal, observational study in pregnant women who will be randomized to received either a Blinded or Unblinded CGM sensor and followed-up 6-12 weeks after delivery:

Read full original descriptionShow less

1. CF-CGM device is well tolerable and accurate for glucose level monitoring in women with a normal pregnancy. 2. CF-CGM device is well tolerable and acceptable in women with GDM who are required intensive glucose monitoring on a daily basis during pregnancy and even after delivery. 3. There are trimester-specific glucose profiles observed in the whole pregnancy. 4. Pregnancies complicated with GDM would show a specific glucose profile that is different from non-GDM pregnancies (e.g. greater daily fluctuations, more episodes and longer duration of glucose spikes after meal). 5. There is a good correlation between one-day glucose profile and OGTT test at 24-31 weeks gestation GDM screening. 6. Pre-GDM screening glucose profiles is predictive of GDM diagnosis at 24-31 weeks gestation.

The 2 groups in the trial

  • Blinded GroupTreatment being tested

    Participants in the blinded group will be wearing the sensor for 14 days without a reader. After 14 days, participants are required to scan the sensor themselves or with the assistance of a CRC to a designated blinded-reader.

  • Unblinded GroupTreatment being tested

    Participants in the non-blinded group are required to wear the sensor for 14 days with an open reader. The participant will be required to upload their glucose readings no longer than 8 hours by scanning the reader provided.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
10 October 2024